Drugs / Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate
Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00387738 | Apr 2006 → May 2007 | seasonal allergic rhinitis | Dynavax Technologies Corporation | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00387738 ↗ |
| Modality | Oligonucleotide (other) | “Biological: Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate” NCT00387738 ↗ |
| Route | Subcutaneous | “Escalating doses, 6 weekly subcutaneous (under the skin) injections” NCT00387738 ↗ |